Drug profile

The FDA adverse-event record for Imidacloprid, Permethrin, Pyriproxyfen

28 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Imidacloprid, Permethrin, Pyriproxyfen. See the species affected, top reactions, and outcomes below.

28
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
10
Lack of efficacy (ectoparasite) - flea - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
28
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Imidacloprid, Permethrin, Pyriproxyfen

Administration Routes

Topical

Species Affected

Dog 28

Most Affected Breeds

Spitz - German Pomeranian 9
Retriever - Labrador 2
Mixed (Dog) 2
Shepherd Dog - German 2
Collie - Rough-haired 1
Shih Tzu 1
Akita 1
Plott 1
Pit Bull 1
Shepherd Dog (unspecified) 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 10
Decreased appetite 5
Lethargy (see also Central nervous system depression in 'Neurological') 4
Vomiting 3
Vocalisation 2
Diarrhoea 2
Behavioural disorder NOS 1
Ataxia 1
Fever 1
Musculoskeletal pain 1
Agitation 1
Localised pain NOS (see other 'SOCs' for specific pain) 1

Outcome Breakdown

Outcome Unknown
18 (64.3%)
Recovered/Normal
7 (25.0%)
Ongoing
3 (10.7%)

Imidacloprid, Permethrin, Pyriproxyfen Adverse Event Insights

28 reports name Imidacloprid, Permethrin, Pyriproxyfen; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Imidacloprid, Permethrin, Pyriproxyfen. Administration route: Topical.

By species: Dog (28 reports). By breed: Spitz - German Pomeranian (9), Retriever - Labrador (2), Mixed (Dog) (2).

Leading clinical signs: Lack of efficacy (ectoparasite) - flea (10), Decreased appetite (5), Lethargy (see also Central nervous system depression in 'Neurological') (4), Vomiting (3). Outcome, 28 coded reports: Outcome Unknown leads at 64.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.